Adult Clinical Trials

Leukemia and multiple myeloma

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Leukemia Clinical Trials Office at 919.681.4769 or the Multiple Myeloma Clinical Trial Office at 919.668.6524.

31 trials identified.

Genetic Epidemiology of Chronic Lymphocytic Leukemia
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: J Brice Weinberg
Contact: Ruth Stanton
Phone: 919.416.8029
Reference Number: 00005573
View this trial at ClinicalTrials.gov

An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Murat Arcasoy
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00031423
View this trial at ClinicalTrials.gov

AAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Reference Number: 00031615
View this trial at ClinicalTrials.gov

Safety and Efficacy of Chemotherapy combined with Adoptive Transfer of HLA-Haploidentical Donor Lymphocyte Infusion in Older Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Anthony Sung
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00043247
View this trial at ClinicalTrials.gov

A Phase I Study of L-Asparaginase Encapsulated in Red Blood Cells (eryaspase) in Combination with the CALGB Regimen During Induction and Consolidation Phases for Adult Patients with Acute Lymphoblastic Leukemia
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00046940
View this trial at ClinicalTrials.gov

A Multicenter Phase 1/2b Study of the Brutons Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with relapsed or relapsed and refractory Multiple Myeloma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.6524
Reference Number: 00049683
View this trial at ClinicalTrials.gov

SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.4769
Reference Number: 00050098
View this trial at ClinicalTrials.gov

A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00057708
View this trial at ClinicalTrials.gov

A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients with Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated with Proteasome Inhibitors and Immunomodulatory Drugs.
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Yubin Kang
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.6524
Reference Number: 00062304
View this trial at ClinicalTrials.gov

A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Danielle Brander
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00062914
View this trial at ClinicalTrials.gov

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Joseph Moore
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00064341
View this trial at ClinicalTrials.gov

Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919 .681.4769
Reference Number: 00064933
View this trial at ClinicalTrials.gov

A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia or CD25-positive Acute Lymphoblastic Leukemia
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00066343
View this trial at ClinicalTrials.gov

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Carlos Decastro
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00066615
View this trial at ClinicalTrials.gov

A Phase 1/2 Open label Study of SL-401 in combination with Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.6524
Reference Number: 00069269
View this trial at ClinicalTrials.gov

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.6524
Reference Number: 00069273
View this trial at ClinicalTrials.gov

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Danielle Brander
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00070143
View this trial at ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Nave to Proteasome Inhibitors
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT HEME Malignancy Clinical Trials Oncology Office
Phone: 919.668.1979
Reference Number: 00071288
View this trial at ClinicalTrials.gov

S1318: A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Leukemia Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00072067
View this trial at ClinicalTrials.gov

Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Patients Unfit for Standard Chemotherapy
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00072423
View this trial at ClinicalTrials.gov

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Danielle Brander
Contact: Leukemia Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00072486
View this trial at ClinicalTrials.gov

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.6524
Reference Number: 00072528
View this trial at ClinicalTrials.gov

A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Danielle Brander
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00072590
View this trial at ClinicalTrials.gov

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Danielle Brander
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00072597
View this trial at ClinicalTrials.gov

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00072859
View this trial at ClinicalTrials.gov

An open-label, dose-escalation and multi-center study to evaluate the safety and pharmacokinetics of SAR650984 in patients with relapsed/refractory multiple myeloma (RRMM).
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Cristina Gasparetto
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.668.1979
Reference Number: 00074327
View this trial at ClinicalTrials.gov

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Carlos Decastro
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00075114
View this trial at ClinicalTrials.gov

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00075546
View this trial at ClinicalTrials.gov

A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Carlos Decastro
Contact: BMT HEME Malignancy Clinical Trials Oncology Office
Phone: 919.681.4769
Reference Number: 00076420
View this trial at ClinicalTrials.gov

A PHASE 2, MULTICENTER, MULTI-COHORT, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOWDOSE DEXAMETHASONE AND DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA FOLLOWING LENALIDOMIDE-BASED THERAPY IN THE FIRST OR SECOND LINE SETTING
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Yubin Kang
Contact: BMT HEME Malignancy Clinical Trials Oncology Office
Phone: 919.668.2331
Reference Number: 00077230
View this trial at ClinicalTrials.gov

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancer
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00077362
View this trial at ClinicalTrials.gov